67 related articles for article (PubMed ID: 1570232)
1. Use of nonlinear, mixed-effects modeling for population analysis of ofloxacin: effects of age on oral drug pharmacokinetics.
Yuen GJ; Drusano GL; Brooks J; Flor S
Pharmacotherapy; 1992; 12(2):88-92. PubMed ID: 1570232
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacokinetics of ofloxacin administered orally in elderly subjects with bronchial or urinary tract infections].
Bardin C; Clavier M; Darchis JP; Chauvin M; Veyssier P; Farinotti R
Therapie; 1992; 47(1):35-9. PubMed ID: 1523592
[TBL] [Abstract][Full Text] [Related]
3. Two open-label, randomized, crossover studies assessing the bioequivalence of ofloxacin administered as immediate-and extended-release formulations in healthy subjects.
Marier JF; Ducharme MP; DiMarco M; Di Spirito M; Morelli G; Tippabhotla SK; Badri N; Rampal A; Monif T
Clin Ther; 2006 Dec; 28(12):2070-80. PubMed ID: 17296463
[TBL] [Abstract][Full Text] [Related]
4. Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis.
Anderson BJ; Pons G; Autret-Leca E; Allegaert K; Boccard E
Paediatr Anaesth; 2005 Apr; 15(4):282-92. PubMed ID: 15787918
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and safety of single rising doses of ofloxacin in healthy volunteers.
Marchbanks CR; Dudley MN; Flor S; Beals B
Pharmacotherapy; 1992; 12(1):45-9. PubMed ID: 1549538
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and relative bioavailability of ofloxacin tablets in 12 healthy volunteers.
Diao Y; Li L; Zhou GH; Cheng Y
Zhongguo Yao Li Xue Bao; 1992 Mar; 13(2):110-2. PubMed ID: 1598824
[TBL] [Abstract][Full Text] [Related]
7. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of ofloxacin in drug-resistant tuberculosis.
Chulavatnatol S; Chindavijak B; Chierakul N; Klomsawat D
J Med Assoc Thai; 2003 Aug; 86(8):781-8. PubMed ID: 12948278
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and tissue distribution of ofloxacin in human subjects during a multiple dose regimen.
De Bernardis E; Bonaccorsi S; Carlino S; Picari M; Rizza V
Int J Clin Pharmacol Res; 1988; 8(4):239-45. PubMed ID: 3182113
[TBL] [Abstract][Full Text] [Related]
10. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
Zhou H; Mayer PR; Wajdula J; Fatenejad S
J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
[TBL] [Abstract][Full Text] [Related]
11. Application of NONMEM method for evaluation of relative biological availability of ofloxacin.
Li Z; Chen G; Zhuo HT
Zhongguo Yao Li Xue Bao; 1994 Jan; 15(1):39-42. PubMed ID: 8010083
[TBL] [Abstract][Full Text] [Related]
12. Dose related pharmacokinetics of ofloxacin in healthy volunteers.
Immanuel C; Hemanthkumar AK; Gurumurthy P; Venkatesan P
Int J Tuberc Lung Dis; 2002 Nov; 6(11):1017-22. PubMed ID: 12475149
[TBL] [Abstract][Full Text] [Related]
13. Bioavailability of two oral formulations of a single dose of levofloxacin 500 mg: an open-label, randomized, two-period crossover comparison in healthy Mexican volunteers.
Galan-Herrera JF; Poo JL; Rosales-Sanchez O; Fuentes-Fuentes E; Cariño L; Burke-Fraga V; Namur S; Parra MG
Clin Ther; 2009 Aug; 31(8):1796-803. PubMed ID: 19808138
[TBL] [Abstract][Full Text] [Related]
14. Safety and pharmacokinetics of single dose intravenous ofloxacin in healthy volunteers.
Guay D; Tack K; Flor S
Int J Clin Pharmacol Res; 1991; 11(5):203-9. PubMed ID: 1814841
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of ofloxacin in broiler chicken.
Kalaiselvi L; Sriranjani D; Ramesh S; Sriram P; Mathuram LN
J Vet Pharmacol Ther; 2006 Jun; 29(3):185-9. PubMed ID: 16669862
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting.
Nakade S; Ohno T; Kitagawa J; Hashimoto Y; Katayama M; Awata H; Kodama Y; Miyata Y
Cancer Chemother Pharmacol; 2008 Dec; 63(1):75-83. PubMed ID: 18317761
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of ofloxacin. An overview.
Flor S
Am J Med; 1989 Dec; 87(6C):24S-30S. PubMed ID: 2603892
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
Guo F; Letrent SP; Sharma A
Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy.
Chhun S; Jullien V; Rey E; Dulac O; Chiron C; Pons G
Epilepsia; 2009 May; 50(5):1150-7. PubMed ID: 19175400
[TBL] [Abstract][Full Text] [Related]
20. The effect of binders on the bioavailability of ofloxacin tablets in animal model.
Rasool F; Ahmad M; Khan HM; Akhtar N; Murtaza G
Acta Pol Pharm; 2010; 67(2):185-9. PubMed ID: 20369796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
